Express Scripts (ESRX): Health Services' Starring Winner Of The Day

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Express Scripts ( ESRX) pushed the Health Services industry higher today making it today's featured health services winner. The industry as a whole closed the day up 0.9%. By the end of trading, Express Scripts rose 77 cents (1.3%) to $58.11 on average volume. Throughout the day, 4.5 million shares of Express Scripts exchanged hands as compared to its average daily volume of 5.9 million shares. The stock ranged in a price between $57.42-$58.48 after having opened the day at $57.63 as compared to the previous trading day's close of $57.34. Other companies within the Health Services industry that increased today were: Spherix ( SPEX), up 12.2%, Cardica ( CRDC), up 8%, Masimo Corporation ( MASI), up 6.6%, and Iridex Corporation ( IRIX), up 6%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Express Scripts Holding Company provides a range of pharmacy benefit management (PBM) services primarily in the United States and Canada. It offers healthcare management and administration services on behalf of its clients. Express Scripts has a market cap of $46.96 billion and is part of the health care sector. The company has a P/E ratio of 32, above the S&P 500 P/E ratio of 17.7. Shares are up 6.2% year to date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Express Scripts a buy, no analysts rate it a sell, and three rate it a hold.

TheStreet Ratings rates Express Scripts as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, reasonable valuation levels, increase in net income, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the negative front, Health Management Associates ( HMA), down 16.4%, Harvard Bioscience ( HBIO), down 13.6%, Urologix ( ULGX), down 8.2%, and Bio-Reference Labs ( BRLI), down 7.4%, were all laggards within the health services industry with HCA Holdings ( HCA) being today's health services industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.
null

If you liked this article you might like

Here's How to Invest Like a Billionaire

The Dow Binges on Earnings

Alphabet Slides After a So-So Quarter - 5 Things You Must Know Before the Market Opens